1,577 followers
@GanLee_ (SHSE: 603087) announced that its Phase 1 study on glargine U300 was published in Frontiers in Endocrinology. The study confirms that its glargine U300 is bioequivalent to the reference drug, demonstrating similar safety and efficacy. #QMPortfolio